Biomarkers Differentiating Dementia with Lewy Bodies from Other Dementias: A Meta-Analysis

Mishima, Aki; Nishizaki, Takashi; Ando, Yumiko; Kawai, Hisashi; Kato, Takashi; Ito, Kengo; Terasawa, Teruhiko

doi:10.3233/jad-150675

Cited by 8 publications

(3 citation statements)

References 87 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…The current review updates the meta-analysis performed by Nihashi et al in 2018, which itself was an update of their 2015 meta-analysis [ 6 , 78 ]. Since we did not perform a meta-analysis, we did not compare specificities and sensitivities with these previous studies.…”

Section: Discussionmentioning

confidence: 86%

The diagnostic performance of functional dopaminergic scintigraphic imaging in the diagnosis of dementia with Lewy bodies: an updated systematic review

Jreige

Kurian

Perriraz

et al. 2023

Eur J Nucl Med Mol Imaging

View full text Add to dashboard Cite

Introduction Dopaminergic scintigraphic imaging is a cornerstone to support the diagnosis in dementia with Lewy bodies. To clarify the current state of knowledge on this imaging modality and its impact on clinical diagnosis, we performed an updated systematic review of the literature. Methods This systematic review was carried out according to PRISMA guidelines. A comprehensive computer literature search of PubMed/MEDLINE, EMBASE, and Cochrane Library databases for studies published through June 2022 was performed using the following search algorithm: (a) "Lewy body" [TI] OR "Lewy bodies" [TI] and (b) ("DaTscan" OR "ioflupane" OR "123ip" OR "123?ip" OR "123 ip" OR "123i-FP-CIT" OR "FPCIT" OR "FP-CIT" OR "beta?CIT" OR "beta CIT" OR "CIT?SPECT" OR "CIT SPECT" OR "Dat?scan*" OR "dat scan*" OR "dat?spect*" OR "SPECT"). Risk of bias and applicability concerns of the studies were evaluated using the QUADAS-2 tool. Results We performed a qualitative analysis of 59 studies. Of the 59 studies, 19 (32%) addressed the diagnostic performance of dopamine transporter imaging, 15 (25%) assessed the identification of dementia with Lewy bodies in the spectrum of Lewy body disease and 18 (31%) investigated the role of functional dopaminergic imaging in distinguishing dementia with Lewy bodies from other dementias. Dopamine transporter loss was correlated with clinical outcomes in 19 studies (32%) and with other functional imaging modalities in 15 studies (25%). Heterogeneous technical aspects were found among the studies through the use of various radioligands, the more prevalent being the [123I]N‑ω‑fluoropropyl‑2β‑carbomethoxy‑3β‑(4‑iodophenyl) nortropane (123I-FP-CIT) in 54 studies (91.5%). Image analysis used visual analysis (9 studies, 15%), semi-quantitative analysis (29 studies, 49%), or a combination of both (16 studies, 27%). Conclusion Our systematic review confirms the major role of dopaminergic scintigraphic imaging in the assessment of dementia with Lewy bodies. Early diagnosis could be facilitated by identifying the prodromes of dementia with Lewy bodies using dopaminergic scintigraphic imaging coupled with emphasis on clinical neuropsychiatric symptoms. Most published studies use a semi-quantitative analytical assessment of tracer uptake, while there are no studies using quantitative analytical methods to measure dopamine transporter loss. The superiority of a purely quantitative approach to assess dopaminergic transmission more accurately needs to be further clarified.

show abstract

Section: Discussionmentioning

confidence: 86%

The diagnostic performance of functional dopaminergic scintigraphic imaging in the diagnosis of dementia with Lewy bodies: an updated systematic review

Jreige

Kurian

Perriraz

et al. 2023

Eur J Nucl Med Mol Imaging

View full text Add to dashboard Cite

show abstract

“…To address topics other than COVID-19, we used several previous DTA systematic reviews, including those on malignancy, 18 gastrointestinal disorders, 19 respiratory disorders, 20 emergency care, 21,22 neurology, [23][24][25] and infectious disease. 26,27 Some search data were not stored in a reusable form, and fewer records were included than those retrieved for the original studies.…”

Section: Preparation Of Datasetsmentioning

confidence: 99%

An open competition involving thousands of competitors failed to construct useful abstract classifiers for new diagnostic test accuracy systematic reviews

Kataoka

Taito

Yamamoto

et al. 2023

Research Synthesis Methods

Self Cite

View full text Add to dashboard Cite

There are currently no abstract classifiers, which can be used for new diagnostic test accuracy (DTA) systematic reviews to select primary DTA study abstracts from database searches. Our goal was to develop machine‐learning‐based abstract classifiers for new DTA systematic reviews through an open competition. We prepared a dataset of abstracts obtained through database searches from 11 reviews in different clinical areas. As the reference standard, we used the abstract lists that required manual full‐text review. We randomly splitted the datasets into a train set, a public test set, and a private test set. Competition participants used the training set to develop classifiers and validated their classifiers using the public test set. The classifiers were refined based on the performance of the public test set. They could submit as many times as they wanted during the competition. Finally, we used the private test set to rank the submitted classifiers. To reduce false exclusions, we used the Fbeta measure with a beta set to seven for evaluating classifiers. After the competition, we conducted the external validation using a dataset from a cardiology DTA review. We received 13,774 submissions from 1429 teams or persons over 4 months. The top‐honored classifier achieved a Fbeta score of 0.4036 and a recall of 0.2352 in the external validation. In conclusion, we were unable to develop an abstract classifier with sufficient recall for immediate application to new DTA systematic reviews. Further studies are needed to update and validate classifiers with datasets from other clinical areas.

show abstract

“…Im Vergleich erscheinen sowohl die [ 123 I]FP-CIT-SPECT als auch die [ 123 I]MIBG-Szintigraphie der [ 18 F]FDG-PET für die Differenzierung DLK vs. AD überlegen (Metaanalyse: [ 50 ]; DAT-SPECT vs. [ 18 F]FDG-PET: [ 33 , 51 ]). In Head-to-head-Vergleichen weisen die beiden erstgenannten Methoden eine vergleichbare diagnostische Eignung [ 52 , 53 ] bzw.…”

Section: Bildgebungunclassified

Dementia with Lewy bodies: old and new knowledge – Part 1: clinical aspects and diagnostics

Dodel,

Berg,

Duning

et al. 2023

Nervenarzt

View full text Add to dashboard Cite

Zusammenfassung Hintergrund Die Demenz mit Lewy-Körpern (DLK) ist nach der Alzheimer-Krankheit die zweithäufigste neurodegenerative Demenzerkrankung. Patienten mit DLK haben oft eine schlechte Prognose, mit schlechteren Ergebnissen als Patienten mit der Alzheimer-Krankheit in Bezug auf wichtige Parameter wie Lebensqualität, Belastung der Pflegepersonen, gesundheitsbezogene Kosten, Einweisungshäufigkeit in Krankenhäuser und Pflegeheime, kürzerer Zeitraum bis zur schweren Demenz und eine geringere Überlebensrate. Die DLK wird häufig fehldiagnostiziert und ist oft unterbehandelt. Daher ist es von entscheidender Bedeutung, die DLK so früh wie möglich zu diagnostizieren, um eine optimale Versorgung und Behandlung zu gewährleisten. Ziel der Arbeit In diesem Übersichtsartikel sollen die wichtigsten neuen Erkenntnisse zu diagnostischen Instrumenten, der Epidemiologie und Genetik der Demenz mit Lewy-Körpern zusammengetragen werden. Ergebnisse Es existieren präzise klinischen Diagnosekriterien für die DLK, die eine ätiologische Zuordnung zulassen. Bildgebende Verfahren kommen standardmäßig bei der DLK zum Einsatz, insbesondere auch, um nicht neurodegenerative Ursachen auszuschließen. Insbesondere nuklearmedizinische Verfahren besitzen eine hohe diagnostische Aussagekraft. Diskussion Die Diagnose beruht in erster Linie auf der klinischen Symptomatik, obwohl die Entwicklung von In-vivo-Neurobildgebung und Biomarkern den Umfang der klinischen Diagnose sowie die Erforschung dieser verheerenden Krankheit verändert.

show abstract

Biomarkers Differentiating Dementia with Lewy Bodies from Other Dementias: A Meta-Analysis

Cited by 8 publications

References 87 publications

The diagnostic performance of functional dopaminergic scintigraphic imaging in the diagnosis of dementia with Lewy bodies: an updated systematic review

The diagnostic performance of functional dopaminergic scintigraphic imaging in the diagnosis of dementia with Lewy bodies: an updated systematic review

An open competition involving thousands of competitors failed to construct useful abstract classifiers for new diagnostic test accuracy systematic reviews

Dementia with Lewy bodies: old and new knowledge – Part 1: clinical aspects and diagnostics

Contact Info

Product

Resources

About